Alivus Life Sciences Ltd.

Nirma has completed acquisition of 91,895,379 equity shares, representing 75% of the current issued and paid-up equity share capital of Glenmark Life Sciences from Glenmark Pharmaceuticals.

Under the terms of the share purchase agreement, Nirma has purchased 75% of the current issued and paid-up equity share capital of Glenmark Life Sciences, consolidating its position as the new promoter of the company. This strategic acquisition marks a significant milestone for Nirma as it strengthens its presence in the pharmaceuticals and life sciences sector.

Glenmark Life Sciences is in the business of making high-quality drugs by unlocking the possibilities of science.